balertatug   Click here for help

GtoPdb Ligand ID: 13800

Immunopharmacology Ligand
Compound class: Antibody
Comment: Balertatug is the INN for an anti-CD70 monoclonal antibody. Peptide sequence matches this to claims in patent US8067546B2; Humanized anti-CD70 binding agents and uses thereof [1]. May align with SeaGen's clinical candidate SGN-70/SEA-CD70 that was developed for antitumour activity against CD70-positive cancers (principally myelodysplastic syndrome and acute myeloid leukemia) [2]. The antibody blocks activation of the CD70/CD27 signalling pathway that promotes stemness and proliferation of leukemic blasts. It is engineered to enhance effector functions; antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). Internal company identifier was switched to PF-08046040 when Pfizer acquired SeaGen.
Bioactivity Comments
SGN-70/SEA-CD70 lyses CD70+ve tumour cells via Fc-dependent functions, including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis [2].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD70 Hs Antibody Binding 9.2 – 9.4 pKd - 1
⤷ pKd 9.4 (Kd 3.7x10-10 M) [1]
Description: Binding affinity of Europium-labeled antibody h1F6 HJLA to CD70 positive Caki-2 cells
pKd 9.2 (Kd 6.8x10-10 M) [1]
Description: Binding affinity of Europium-labeled antibody h1F6 HJLA to CD70 positive ACHN cells